Rafarma Pharmaceuticals, Inc. (RAFA)

Take a look at some of our previously featured companies

Rafarma Pharmaceuticals, Inc. (RAFA)

Postby QualityStocks » Fri Feb 15, 2013 4:46 pm

Rafarma Pharmaceuticals, Inc. is a multiproduct pharmaceutical company specializing in the production of generic antibiotics and specialty pharmaceuticals, including its own proprietary products approved by the ministry of health. Rafarma stands as one of the most ambitious projects in recent medical history, having constructed the most technologically advanced pharmaceutical plant in Russia.

Based in Terbuny, Lipetsk region, Russia, Rafarma possesses a unique niche in the burgeoning pharmaceutical market and is poised to become a major player in the international drug industry. The company was established under the auspices of the Foundation to Support Health Care and has been approved by the Ministry of Health.

Rafarma recently received the general license for pharmaceutical products and began manufacturing three new products: Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Receiving the general license was one of the final steps the company needed to open its new plant in Terbuniv, and Rafarma has been named one of only four national strategic pharmaceutical suppliers to the Russian Federation.

Advances in health care science, medicine, and technology have increased the general life expectancy of Eastern European citizens steadily over the past decade. Elderly citizens, which comprise the largest portion of the pharmaceuticals market, have bolstered demand for pharmaceuticals nationwide. Rafarma is well positioned to capitalize on the expanding industry with its strong relationships and state-of-the-art production facility.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 605
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby stockseeker30 » Fri Feb 15, 2013 11:34 pm

Sounds like RAFA knows how to focus on the there clientel they should do well with the entire baby boomer classs .
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 0
Joined: Sat Aug 21, 2010 9:02 pm

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby mwest » Sat Feb 16, 2013 12:25 am

Oh the Baby Boomers that is a group that will affect a lot
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 0
Joined: Thu Apr 09, 2009 3:09 pm

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby QualityStocks » Tue Mar 26, 2013 7:29 am

Rafarma Pharmaceuticals, Inc. (RAFA) Achieves Full Certification

Rafarma Pharmaceuticals announced that its manufacturing and packaging facility in Lipetsk, Russia was fully licensed last November 9th and exhibited by GMP (“Good Manufacturing Practices”) Certificate # 109489 7000-430 (see: http://rafarma.com).

The facility is ISO 9001 and IHC Q 10 compliant. These internationally recognized certifications allow sales and distribution of all permitted products throughout Europe and all nations that are a party to the above standards. The manufacturing facility is currently operating at 30% capacity during its “start-up” phase, and is expected to reach full production during the second quarter of 2013.

With the resignation of Vladimir Bondar as Director and President and Natalia Leonidovna Stupina as Director and CFO due to other commitments, the Company appointed Mr. Sergey Brusnitsin as its new Director and CFO. Mr. Brusnitsin earned his PhD in Economics from the Moscow Institute of Economics and was formerly the director of the Federal Revenue Service of Russia. He has been affiliated with the Company in several capacities throughout its development phase. Mr. Alexander Ageev continues to function as Director, Secretary/Treasurer and Mr. David Anderson will remain as Director and CEO and perform the function of President until the first annual meeting, now scheduled for March 1, 2013.

With expended development costs in excess of $200 million, and expected first year revenue expectations exceeding $100 million, and an excellent product portfolio, the Company is expected to be a leading supplier of pharmaceuticals in the years to come.

The new OTC trading symbol for the Company will be announced by FINRA on January 2, 2013 and be effective January 3, 2013.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 605
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby QualityStocks » Tue Mar 26, 2013 7:29 am

Rafarma Pharmaceuticals, Inc. (RAFA) Named 1 Of 4 National Strategic Pharmaceutical Suppliers To The Russian Federation

Rafarma Pharmaceuticals announced that it has been named one of the four national strategic Pharmaceutical Suppliers to the Russian Federation. This important step for the company means it will receive guaranteed government contracts helping load the manufacturing facility to 100% capacity.

The Russian pharmaceutical industry supplies both the national health care system and hospital sector with 70% of medicines in physical volume. The Russian pharmaceutical market is considered to be one of the most dynamic and growing in the world. It continues to grow an average 10-12% per year since 2003 (Source: The Strategy of Development of the Pharmaceutical Industry of the Russian Federation, http://www.osec.ch/de/filefield-private ... files/5244).

CEO David Anderson stated, “This is a very exciting time for the Company and we are extremely happy with the ability to be one of the four national strategic Pharmaceutical Suppliers to the Russian Federation.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 605
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby QualityStocks » Tue Mar 26, 2013 7:29 am

Rafarma Pharmaceuticals, Inc. (RAFA) Receives General License for Pharmaceutical Products

Rafarma Pharmaceuticals announced that it has received the general license for pharmaceutical products and has started the manufacturing of 3 new products. The general license was one of the final steps required to open the new plant in Terbuniy. The Company is now in operation and is expected to rapidly increase to 100% capacity of the Terbiniy facility with the addition of government contracts provided by being 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation.

The new products are Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Sodium Para-Aminosalicilate is a tablet with a time release cover. The current dosage manufactured is 1000 mg and is designed to be of use against various forms of tuberculosis. Sodium Para-Aminosalicilate can also be used in conjunction with other anti-tuberculosis medications. The Ibuprofen manufactured is Rectal Suppositories for children and the currently manufactured dosage is 60 mg. Betagistin Tablets are manufactured in dosages of 8 mg, 16 mg and 24 mg. The product is used to treat Manier Syndrome which is characterized by drowsiness, nausea, reduction in hearing abilities and noise in the ears. It is also used as treatment of vestibular vertigo.

Julia Andrushkova, a company spokesperson, was quoted as saying: “Receiving the general license for pharmaceutical products has been a major step to success for the many people involved, and for the Company in general.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 605
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby protostars » Mon Apr 01, 2013 7:54 am

RAFA represents a massive opportunity to further build up the pharmaceutical industry supplying not only Russia but anywhere they can crack the market. This is a ground floor opportunity, and it's being actively supported by the government.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby QualityStocks » Mon Apr 08, 2013 8:32 am

Rafarma Pharmaceuticals, Inc. (RAFA) Reports Registration of CEFTRIAXONE Under International Label

Rafarma Pharmaceuticals, a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, just announced that ZAO “Rafarma” has registered (MHH) CEFTRIAXONE, a third-generation cephalosporin antibiotic, as a medication under international unpatented label.

The antibiotic is typically used in combination for the treatment of pneumonia, bacterial meningitis, gonorrhea, and in pediatrics for the prevention of sepsis. According to today’s press release, market capacity of CEFTRIAXONE in the Russian Federation last year totaled USD $85.7 million dollars, an increase of 20% compared to its capacity in 2011.

Dave Anderson, CEO of Rafarma Pharmaceuticals, said, “Registering this product is complementary to our goal of producing high-quality pharmaceutical products. Rafarma is positioned to meet rising market demand for CEFTRIAXONE utilizing our state-of-the-art research facility and staff as we continue efforts to expand our product portfolio.”

“I’d also like to clarify that Rafarma’s earlier announcement reporting its status as 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation in no way limits our ability to produce and manufacture products for qualified buyers globally,” added Mr. Anderson. “We will offer CEFTRIAXONE, as well as all other products we produce, to the international market.”

For more information, visit www.Rafarma.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 605
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby mwest » Mon Apr 08, 2013 9:32 pm

keeping the Baby Boomers alive longer can haves its upside in the economy
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 0
Joined: Thu Apr 09, 2009 3:09 pm

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby protostars » Tue Apr 09, 2013 6:20 am

Ceftriaxone is a basic antibiotic that can be used in the treatment of things like pneumonia, bacterial meningitis, and even typhoid.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby QualityStocks » Tue Apr 09, 2013 9:36 am

QualityStocks Travels Overseas to Scope-out Rafarma Pharmaceuticals, Inc. (RAFA)

What does your typical due diligence look like? Pouring over earnings, contacting investor relations, compiling industry statistics, and scanning message boards and newsletters? When considering the investment of your hard-earned money into a company, would you go so far as to take a trip to its physical location? What if the company is headquartered overseas?

QualityStocks managing director Michael McCarthy has set a high bar for due diligence on behalf of the investment community, boarding a plane to fly more than 6,000 miles to Southern Moscow to see Rafarma Pharmaceuticals’ sprawling 270,000 square-foot pharmaceutical production facility for himself.

It may seem like a drastic measure until you consider the skepticism reverse-merger Chinese companies have triggered in the small-cap space in recent years. In 2011, toxicity from illicit reverse-merger companies bled through the Chinese sector and prompted an SEC bulletin warning investors of potential fraud in the arena and how to avoid it. The ordeal left a foul residue on the entire Chinese sector and overseas-based small caps in general, whether they were derived from reverse-merger or not. But the potential of one Russia-based pharmaceutical was enough to spark the interest of McCarthy, who responded to Rafarma’s invite and loaded up the QualityStocks camera crew to fully vet the management and operations of the company on its own soil.

“This client stands out because its state-of-the-art pharmaceutical plant has taken four years of persistent effort and massive investment to get to this point. The other side is that with the onslaught of all the funky China deals, Russia-based companies are often met with skepticism from investors,” McCarthy stated. “On paper Rafarma’s plant looks amazing, but looks can be deceiving. So we brought our camera crew to produce an HD video of the facility, which we will share with investors very soon.”

Rafarma is a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. The company recently constructed a world-class manufacturing facility capable of producing all types and forms of medical drugs of various pharmacological groups.

The Location

Rafarma is located in the economic zone of Terbunsky, Russia, roughly 300 km south of Moscow, the highly modernized megacity boasting more than 11.5 million residents. The city is the financial epicenter of Russia, with many business sectors, including pharmaceuticals, achieving outstanding growth rates as the Russian government executes a comprehensive strategy to encourage domestic growth and minimize the nation’s dependence on foreign medicines.

Rafarma’s state-of-the-art pharmaceutical plant has been supported by the government of Lipetsk region of Russia, the Ministry of Health of Russian Federation, and the Ministry of Industry and Trade of Russian Federation, which listed Rafarma as one of the leading and most prospective projects in the modern Russian pharmaceutical and medical industry. All this sounds impressive on paper, but the real value lies in the impressive brick and mortar facility itself.

The three-level facility is surrounded by guards and barbed wire, which are reinforced by security checkpoints and key card access throughout the entire facility. What struck McCarthy first and foremost was the sheer size of the facility. Rafarma owns 75 acres, 5 of which are occupied by the company’s manufacturing plant. The remaining acreage serves as a cushion against land lock, and also provides ample room for future expansion. Because the facility is located in an economic zone, when the plant is fully operational it will be exempt from paying local taxes for the first five years of operations.




“Most pharmaceutical plants in the United States and Europe are geographically bound by land lock,” McCarthy stated. “Rafarma, however, has acres and acres of land that will allow it to expand in the future. The Russian pharmaceutical industry is reaching new heights and Rafarma has provided itself the opportunity to grow with it.”

It took two hours for McCarthy and his team to see the entire facility. Rafarma management walked them through different labs and production facilities, which McCarthy describes as immaculately clean, sterile and secure.

“When you see the video the QualityStocks team is producing, you will get a good feel for the plant and its size. But when you’re there in person, hearing and seeing the machines, walking the halls and laboratories, it is absolutely stunning. You’ve got to see it to believe it,” he said.

The Operations

Once the facility is in full operations, it will be a buzzing honeycomb mass producing pharmaceutical products through the entire manufacturing process – from the actual making of the drugs to each pill being sealed in blister packs and shot down a conveyer belt and into packaging where they are boxed, labeled and ready to be shipped out.

As of now Rafarma has 125 employees on its payroll, though the company anticipates increasing its number of employees up to 400 as manufacturing gets underway.

“These guys have the space, equipment and means to run the full spectrum of pharmaceutical operations. From manufacturing to packaging and shipment, they are very close to getting clearance to have all systems on go,” McCarthy explained.




The company’s manufacturing facility is GDP and GDP compliant, and GCP and GMP standards are in their last stages of approval. Rafarma is also working to become GLP compliant, at which time it will be the only Russia-based pharmaceutical company representing the complete cycle of the world’s highest pharmaceutical standards (Good Distribution Practice, Good Clinical Practice, Good Manufacturing Practice, Good Laboratory Practice).

The Future

Rafarma anticipates being completely compliant to industry standards and fully operational by the summer of 2013. The company’s goals are to produce high-quality pharmaceutical products for the domestic market, aiming to reduce prices on certain pharmaceutical products by 30%-40%.

The company is already considered the principle supplier to the Russian Public Health system and the Russian Army, is backed by the biggest bank in Russia, and has invested roughly 100 million euros in its own facilities.

McCarthy notes that big pharmaceutical companies will be drawn to Rafarma’s ability to offer flexibility in meeting mass demand since the company’s facility has the ability to both increase in physical size and maximize capacity.

“This is the Ferrari of pharmaceutical plants,” he said. “The general concern regarding overseas investment may cause some to hesitate, but I believe long term this is going to be a fantastic story. The management team is highly professional and focused. I’m thinking millions of potential profits for these guys long term – they are definitely one-of-a kind.”

The Evidence

Back in the United States, QualityStocks’ media production team is editing hours of video footage of Rafarma’s manufacturing facility and management interviews to produce high-definition videos that fully encapsulate Rafarma’s state-of-the art manufacturing facility and relay its legitimacy, opportunity, and enormity in the best way possible, short of an actual visit to the site. The first trip to Rafarma’s facility was enough to warrant another trip, which QualityStocks has planned later this year to observe the production facility in full swing.

“If Rafarma Pharmaceuticals continues to do what it’s doing and we at QualityStocks can continue to help them grow, we’re going to have a fantastic relationship,” McCarthy stated.

For more information on Rafarma Pharmaceuticals, visit www.rafarma.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 605
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby mwest » Tue Apr 09, 2013 10:43 pm

From 125 to 400 employees you can tell that they are expanding nicely
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 0
Joined: Thu Apr 09, 2009 3:09 pm

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby mwest » Tue Apr 09, 2013 10:43 pm

From 125 to 400 employees you can tell that they are expanding nicely
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 0
Joined: Thu Apr 09, 2009 3:09 pm

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby stockseeker30 » Tue Apr 09, 2013 11:17 pm

And giving hope to many around as they continue to dig ewith ease,
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 0
Joined: Sat Aug 21, 2010 9:02 pm

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby protostars » Wed Apr 10, 2013 7:18 am

Not many outsiders know about the economic activity in this district of Russia, or the Terbunsky special economic zone which encourages industrial growth through special rights to companies, such as reduced taxation.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby QualityStocks » Wed Apr 10, 2013 8:29 am

Rafarma Pharmaceuticals, Inc. (RAFA) Engages QualityStocks Investor Relations Services

Rafarma Pharmaceuticals announced earlier today that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs, and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collates data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts.

Rafarma owns and operates a multi-profile pharmaceutical plant that is able to produce all types and forms of medical drugs in various pharmacological groups. The plant was constructed in the territory of a special industrial economic zone in Terbuny of the Lipetsk region of Russia. The project was initiated by the Zdorovie Foundation and is considered one of the grandest projects of the Russian medical industry in the last few years.

Michael McCarthy, Managing Director of QualityStocks, stated, “We have conducted extensive due diligence and are very excited to inform the investment community of Rafarma’s corporate strategy and ongoing progress. Last month our team traveled over 6,000 miles to visit the company’s 270,000 square-foot plant and take on-site video footage. We will be releasing a series of high-definition videos that fully encapsulate Rafarma’s state-of-the art manufacturing facility and relay its legitimacy, opportunity, and enormity in the best way possible.”

The first video produced by QualityStocks can be viewed at http://Video.QualityStocks.net.

QualityStocks has also put together a detailed, 10-page investor kit as well as a 34-slide presentation, both of which can be found at http://RAFA.QualityStocks.net.

Dave Anderson, CEO of Rafarma Pharmaceuticals, stated, “RAFA has a unique and solid business foundation, and appreciates the opportunity to sponsor the QualityStocks Newsletter, Video and Blogs. QualityStocks is providing a much needed service in the micro-cap and small-cap markets.”

For more information, visit www.Rafarma.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 605
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby stockseeker30 » Wed Apr 10, 2013 3:45 pm

Teaming up with a the newsletter for QualityStocks great exposure to come
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 0
Joined: Sat Aug 21, 2010 9:02 pm

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby mwest » Wed Apr 10, 2013 4:06 pm

Especially since Quality Stocks does it's homework very diligently first
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 0
Joined: Thu Apr 09, 2009 3:09 pm

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby protostars » Thu Apr 11, 2013 6:50 am

For any operation that far away, in a nation that is still in the process of defining its comfort level in a capitalist environment, investors understandably need all the information they can get.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: Rafarma Pharmaceuticals, Inc. (RAFA)

Postby QualityStocks » Thu Apr 11, 2013 8:56 am

To request a 10-page Investor Relations Kit on Rafarma Pharmaceuticals, visit http://dtg.fm/rafa
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 605
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Next

Return to QualityStocks Previous Clients

Who is online

Users browsing this forum: No registered users and 2 guests

cron